Trials / Recruiting
RecruitingNCT05580666
Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 8,000 (estimated)
- Sponsor
- Population Health Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
Detailed description
All participants in the REVIVE trial will be randomized (1:1) at the time of study entry to receive azithromycin prophylaxis or placebo for 28 days and will be followed for 24 weeks to determine the primary outcome measure. Total follow up duration will be 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azithromycin Oral Tablet | Antimicrobial therapy |
| DRUG | Placebo oral tablet | Inert ingredients |
Timeline
- Start date
- 2023-05-08
- Primary completion
- 2028-11-30
- Completion
- 2029-05-31
- First posted
- 2022-10-14
- Last updated
- 2025-09-03
Locations
52 sites across 11 countries: Côte d’Ivoire, Ethiopia, Ghana, Malawi, Mozambique, Nigeria, Rwanda, Sierra Leone, South Africa, Uganda, Zambia
Source: ClinicalTrials.gov record NCT05580666. Inclusion in this directory is not an endorsement.